Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3548 participants.

Also called NCT04499859

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,548 participants (planned count) (from the registry)
Sponsor
Kiyuk Chang, MD,PhD (from the registry)
Registry
  • NCT NCT04499859
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04499859. Randomized; no masking; primary purpose treatment. Start 2020-10-01 (actual); primary completion 2026-08-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
Acronym
ROSUZET-AMI
Condition
Statin Adverse Reaction
Condition
HMG-CoA Reductase Inhibitor Toxicity
Intervention (Drug)
Ezetimibe 10mg + Rosuvastatin 5mg
Intervention (Drug)
Rosuvastatin 20mg
Lead sponsor
Kiyuk Chang, MD,PhD (class: other)

Record details

Record id
cardio:ct-nct04499859
Content hash
5dd29f3c4a54ed32c30b2b0dc8c62477c7957c6cc6568ee04e24374b93c4b389